^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CD19 positive

    i
    Other names: CD19, CD19 Molecule, B-Lymphocyte Surface Antigen B4, T-Cell Surface Antigen Leu-12, Differentiation Antigen CD19, B-Lymphocyte Antigen CD19, CD19 Antigen, CVID3, B4
    Entrez ID:
    930
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    6d
    A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101) (clinicaltrials.gov)
    P1, N=100, Recruiting, MSD R&D (China) Co., Ltd. | Trial primary completion date: Mar 2027 --> Sep 2028
    Trial primary completion date
    |
    IL2 (Interleukin 2)
    |
    CD19 positive
    7d
    International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020) (clinicaltrials.gov)
    P3, N=750, Not yet recruiting, Charite University, Berlin, Germany
    New P3 trial
    |
    CD22 (CD22 Molecule)
    |
    CD19 positive • CD22 positive
    |
    Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin)
    8d
    Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies (clinicaltrials.gov)
    P1, N=61, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Jun 2028 --> May 2026 | Trial primary completion date: Jun 2027 --> May 2026
    Trial completion date • Trial primary completion date
    |
    CD19 positive
    |
    PIT565
    11d
    Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases (clinicaltrials.gov)
    P=N/A, N=12, Recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    New trial • IO biomarker
    |
    CD7 (CD7 Molecule)
    |
    CD19 positive
    11d
    Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=26, Not yet recruiting, City of Hope Medical Center | Initiation date: Jan 2026 --> Jun 2026
    Trial initiation date
    |
    CD19 positive
    |
    clonoSEQ
    |
    Venclexta (venetoclax) • cyclophosphamide • Blincyto (blinatumomab) • vincristine • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn)
    15d
    CD19/ CD22 Bispecific CAR-T Cell Therapy for Relapsed/ Refractory Large B-cell Lymphoma (clinicaltrials.gov)
    P2, N=100, Recruiting, Beijing Tongren Hospital
    New P2 trial
    |
    CD22 (CD22 Molecule)
    |
    CD19 positive • CD22 positive
    15d
    Comprehensive Assessment of CD19 Immunohistochemical Staining in Classic Hodgkin Lymphoma. (PubMed, Am J Surg Pathol)
    On the basis of these findings, CD19 expression on HRS cells should not preclude the pathologic diagnosis of CHL, particularly in the context of mixed-cellularity or EBV+ disease. In addition, older patients with mixed-cellularity and/or EBV+ disease may represent a subgroup of patients with CHL who could benefit from CD19-directed therapies.
    Journal • IO biomarker
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule) • CD79A (CD79a Molecule)
    |
    CD19 positive
    18d
    PIC1 Injection Therapy for Relapsed/Refractory B-NHL (clinicaltrials.gov)
    P1, N=18, Recruiting, Chongqing Precision Biotech Co., Ltd
    New P1 trial
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    CD19 positive • CD20 negative
    21d
    Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies (clinicaltrials.gov)
    P1, N=61, Active, not recruiting, Novartis Pharmaceuticals | N=140 --> 61
    Enrollment change
    |
    CD19 positive
    |
    PIT565
    22d
    Clinical Trial of CMD63 Chimeric Antigen Receptor T-cell (CAR T-cell) in Children With Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov)
    P1, N=16, Recruiting, Chulalongkorn University | Not yet recruiting --> Recruiting | Initiation date: Sep 2025 --> Jan 2026
    Enrollment open • Trial initiation date
    |
    IL7R (Interleukin 7 Receptor)
    |
    CD19 positive
    26d
    YTS109 in Pediatric Relapsed/Refractory Autoimmune Diseases (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, Children's Hospital of Fudan University
    New P1 trial
    |
    CD19 positive
    1m
    IntReALL BCP 2020 International Study for Treatment of Childhood Relapsed Precursor B-cell ALL 2020 (2023-509392-17-00)
    P2/3, N=765, Not yet recruiting, Charite Universitaetsmedizin Berlin KR
    New P2/3 trial
    |
    CD22 (CD22 Molecule)
    |
    CD19 positive • CD22 positive
    |
    cytarabine • Blincyto (blinatumomab) • etoposide IV • Besponsa (inotuzumab ozogamicin) • vincristine • idarubicin hydrochloride • mitoxantrone • mercaptopurine • vindesine